Home Data Calendar Blog

CARA

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Common Stock Value 0.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.040.040.040.040.030.030.030.030.030.030.030.030.030.030.030.020.020.020.020.020.020.00NANA
Weighted Average Number Of Diluted Shares Outstanding 54.2454.0053.87NA53.7353.6153.51NA50.1150.0649.92NA46.8946.8046.72NA44.5239.8239.55NA38.0333.32NA32.5932.2427.30NA27.2827.2827.26NA25.5522.8322.81NA22.7122.6115.65NA4.2915.97
Weighted Average Number Of Shares Outstanding Basic 54.2454.0053.87NA53.7353.6153.51NA50.1150.0649.92NA46.8946.8046.72NA44.5239.8239.55NA38.0333.32NA32.5932.2427.30NA27.2827.2827.26NA25.5522.8322.81NA22.7122.6115.65NA4.294.29
Earnings Per Share Basic -0.52-0.58-0.49-0.56-0.43-0.08-0.52-0.64-0.02-0.61-0.471.60-0.35-0.54-0.62NANANANANANANANANANANANANANANANANANANANANA-0.16NA-0.49-1.070.34
Earnings Per Share Diluted -0.52-0.58-0.49-0.56-0.43-0.08-0.52-0.64-0.02-0.61-0.471.59-0.35-0.54-0.62NANANANANANANANANANANANANANANANANANANANANA-0.16NA-0.49-1.070.33

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Revenue From Contract With Customer Excluding Assessed Tax 4.876.936.173.2610.8123.004.790.8220.270.001.94112.099.275.638.094.515.795.214.385.535.062.870.000.000.000.910.000.000.080.010.002.440.870.490.911.120.960.180.971.029.97
Revenues 4.876.936.173.2610.8123.004.790.8220.270.001.94112.099.275.638.094.515.795.214.385.535.062.870.000.000.000.910.000.000.080.010.002.440.870.490.911.120.960.180.971.029.97
Operating Expenses 33.7639.2733.8134.5734.6627.4832.7034.3421.4030.8825.5033.8026.2931.5238.0934.4840.2229.3527.5227.5125.5320.6914.5712.969.6323.2422.3211.7713.4010.999.737.456.615.215.257.734.673.603.084.563.05
Research And Development Expense 25.4530.3124.3326.0124.6919.9121.2722.8315.5125.2319.1327.1421.0726.1133.5429.8635.9924.3623.6122.8022.3017.0011.589.156.9620.8420.289.6710.768.557.575.584.683.383.466.213.202.201.983.762.02
General And Administrative Expense 6.757.546.896.436.917.579.3511.515.885.656.376.665.225.414.564.624.234.993.914.713.233.693.003.812.672.402.042.102.652.452.161.861.921.821.791.521.471.401.100.801.03
Operating Income Loss -28.90-32.34-27.65-31.31-23.84-4.47-27.91-33.52-1.12-30.88-23.5678.29-17.02-25.88-30.00-29.97-34.43-24.14-23.13-21.98-20.47-17.81-14.57-12.96-9.63-22.32-22.32-11.77-13.33-10.99-9.73-5.01-5.73-4.72-4.34-6.60-3.71-3.42-2.10-3.546.92
Profit Loss -28.03-31.48-26.66-30.34-23.18-4.21-27.75-33.38-1.01-30.75-23.3078.91-16.51-25.07-28.92-28.61-32.84-22.96-21.96-20.65-19.40-17.19-14.18NANANANANANANANANANANANANANANANANANA
Other Comprehensive Income Loss Net Of Tax 0.290.370.57NA-0.10-0.32-1.36NA0.01-0.02-0.06-0.29-0.270.70-0.240.02-0.010.090.19-0.130.070.06-0.110.05-0.040.02-0.02-0.020.040.04NANANANANANANANANANANA
Net Income Loss -28.03-31.48-26.66-30.34-23.18-4.21-27.75-33.38-1.01-30.75-23.3078.91-16.51-25.07-28.92-28.61-32.84-22.96-21.96-20.65-19.40-17.19-14.18-12.44-9.30-22.20-21.97-11.54-13.07-10.69-9.53-4.79-5.68-4.69-4.17-6.54-3.65-3.38-2.09-4.585.34
Comprehensive Income Net Of Tax -27.74-31.11-26.09-29.86-23.28-4.53-29.11-33.74-1.01-30.76-23.3678.62-16.78-24.36-29.16-28.59-32.85-22.87-21.77-20.78-19.33-17.14-14.29-12.39-9.34-22.18-21.99-11.56-13.04-10.65-9.56-4.79-5.68-4.69NANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Assets 115.34134.39153.28182.24213.51226.57223.87247.06225.09221.45250.23271.16147.14168.61196.17232.96263.80149.64170.59190.82212.70139.8997.00108.05117.9743.3063.8380.1592.05102.01110.90117.9046.4451.6555.9362.3768.1971.5618.08NANA
Liabilities And Stockholders Equity 115.34134.39153.28182.24213.51226.57223.87247.06225.09221.45250.23271.16147.14168.61196.17232.96263.80149.64170.59190.82212.70139.8997.00108.05117.9743.3063.8380.1592.05102.01110.90117.9046.4451.6555.93NANANANANANA
Stockholders Equity 85.64108.93136.60158.78184.82204.42204.12227.52207.19203.47230.46249.00127.85140.93160.47186.71211.8999.55114.52133.63149.5373.0886.7899.07109.2229.2750.7371.8082.5994.93105.04113.8642.4747.4251.6655.3461.5764.73-54.08-51.99-48.43

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Assets Current 100.60124.74142.66168.91186.78176.17151.76173.29171.50164.47188.35195.06132.84141.91132.67165.66203.46124.77144.16168.14211.39138.5395.06105.98115.8141.0361.4577.0289.1499.47108.93115.6844.0349.0653.1559.4165.0668.2314.56NANA
Cash And Cash Equivalents At Carrying Value 62.8858.2547.3963.7442.8146.7221.3613.4522.9922.3422.5231.6875.2856.9717.0418.3034.7018.4914.1915.0896.7317.809.3911.799.425.3112.095.433.547.9215.10111.1243.1947.4252.6658.3962.8167.0412.3617.7321.18
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 64.7860.1647.8064.1543.2147.1321.7713.8623.4022.7422.9332.0975.6957.3817.4418.7135.1119.2614.9615.8597.5018.5710.1613.2610.886.7813.56NANANA15.80NANANANANANANANANANA
Accounts Receivable Net Current 3.35NANA3.26NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Inventory Net 3.273.423.522.381.833.461.912.58NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Inventory Finished Goods 0.00NA0.00NANA1.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Available For Sale Securities Debt Securities NANANANANA157.97188.21223.34170.42185.06205.79219.8156.0996.08162.73199.86214.37117.14141.95167.70NANA83.18NANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Property Plant And Equipment Gross NANANA1.83NANANA1.79NANANA2.38NANANA2.03NANANA2.01NANA1.94NANANA9.70NANANA8.28NANANA8.28NANANA8.24NANA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NANANA1.41NANANA1.16NANANA1.54NANANA1.33NANANA1.13NANA0.76NANANA8.09NANANA7.02NANANA6.19NANANA5.42NANA
Property Plant And Equipment Net 1.380.310.370.430.490.550.610.630.650.720.780.840.730.600.650.700.750.800.840.880.910.961.181.301.401.501.611.671.431.071.261.521.711.902.082.262.442.632.83NANA
Available For Sale Debt Securities Amortized Cost Basis NANANANANA160.01189.93223.69170.42185.06205.78219.7355.7395.44162.80199.69214.22116.97141.88167.81109.33114.2283.25NANANA46.18NANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Liabilities Current 22.8825.4616.6823.4628.1921.1718.3017.6215.5315.1716.5218.4816.6024.7332.6042.8948.3040.1642.4140.4543.2434.828.517.277.1912.5111.536.838.176.095.273.373.243.433.406.095.625.755.43NANA
Accounts Payable Current 7.9812.124.429.6015.229.745.595.625.373.394.764.896.484.839.319.109.542.484.944.372.643.693.831.191.861.694.742.392.932.351.971.260.710.940.521.721.191.590.68NANA
Accounts Payable And Accrued Liabilities Current 22.3824.4815.2221.5426.3219.3316.5015.8613.8113.4914.8816.8815.0613.9517.3719.6620.5812.7713.3113.6214.0012.558.517.277.1912.5111.536.838.176.095.273.373.152.461.954.152.552.341.96NANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Operating Lease Liability Noncurrent 6.82NANANA0.500.981.461.922.372.823.253.672.692.963.103.353.60NANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Stockholders Equity 85.64108.93136.60158.78184.82204.42204.12227.52207.19203.47230.46249.00127.85140.93160.47186.71211.8999.55114.52133.63149.5373.0886.7899.07109.2229.2750.7371.8082.5994.93105.04113.8642.4747.4251.6655.3461.5764.73-54.08-51.99-48.43
Common Stock Value 0.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.040.040.040.040.030.030.030.030.030.030.030.030.030.030.030.020.020.020.020.020.020.00NANA
Additional Paid In Capital Common Stock 738.43733.98730.54726.63722.81719.13714.29708.59699.48649.78646.01641.20598.66594.96590.14587.22583.81438.61430.72428.06423.18327.40307.16305.17302.92300.15212.87211.95211.18210.48209.94209.20133.02132.29131.84NANANA8.38NANA
Retained Earnings Accumulated Deficit -652.41-624.38-592.90-566.23-535.89-512.71-508.51-480.76-447.38-446.36-415.62-392.32-471.23-454.72-429.65-400.73-372.12-339.27-316.31-294.35-273.70-254.30-220.34-206.16-193.72-184.42-162.17-140.20-128.66-115.58-104.89-95.36-90.57-84.89-80.20-76.03-69.48-65.84-62.46NANA
Accumulated Other Comprehensive Income Loss Net Of Tax -0.44-0.73-1.10-1.67-2.15-2.05-1.72-0.360.00-0.010.010.070.360.64-0.070.170.150.170.07-0.110.01-0.06-0.070.04-0.010.020.000.020.040.00-0.04NANANA0.00NANANANANANA
Stock Issued During Period Value New Issues 1.12NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA0.000.0056.25NANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 3.173.122.97NA3.524.234.27NA3.493.382.74NA3.312.992.85NA2.832.682.232.031.822.071.751.621.321.110.830.780.700.500.710.660.700.450.340.220.460.350.010.06NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Net Cash Provided By Used In Operating Activities -19.64-20.45-34.62-23.51-25.19-4.50-25.52-1.25-14.12-21.00-23.7282.09-21.62-27.65-38.30-31.17-25.64-24.90-27.53-24.36-20.4941.02-11.41-9.85NANANANANANANANANANANANANANANANANA
Net Cash Provided By Used In Investing Activities 23.1632.8017.7144.4221.1829.6833.43-53.5814.4320.5313.87-164.1639.5467.3836.9614.74-96.8825.2326.40-57.835.45-51.148.1312.08NANANANANANANANANANANANANANANANANA
Net Cash Provided By Used In Financing Activities 1.120.000.560.020.100.180.0045.290.340.290.6938.470.400.200.070.03138.373.970.230.5493.9716.040.180.15NANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Net Cash Provided By Used In Operating Activities -19.64-20.45-34.62-23.51-25.19-4.50-25.52-1.25-14.12-21.00-23.7282.09-21.62-27.65-38.30-31.17-25.64-24.90-27.53-24.36-20.4941.02-11.41-9.85NANANANANANANANANANANANANANANANANA
Net Income Loss -28.03-31.48-26.66-30.34-23.18-4.21-27.75-33.38-1.01-30.75-23.3078.91-16.51-25.07-28.92-28.61-32.84-22.96-21.96-20.65-19.40-17.19-14.18-12.44-9.30-22.20-21.97-11.54-13.07-10.69-9.53-4.79-5.68-4.69-4.17-6.54-3.65-3.38-2.09-4.585.34
Profit Loss -28.03-31.48-26.66-30.34-23.18-4.21-27.75-33.38-1.01-30.75-23.3078.91-16.51-25.07-28.92-28.61-32.84-22.96-21.96-20.65-19.40-17.19-14.18NANANANANANANANANANANANANANANANANANA
Depreciation Depletion And Amortization 0.060.060.060.060.060.060.060.060.060.060.060.060.050.050.050.050.050.050.050.050.080.110.120.120.120.120.120.100.520.730.260.190.190.190.190.200.200.200.200.200.20
Increase Decrease In Inventories -0.15-0.101.130.55-1.621.55-0.68NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Share Based Compensation 3.333.443.353.803.574.665.708.784.393.484.134.073.314.622.853.392.934.012.233.721.822.071.751.621.321.110.830.780.700.500.710.660.700.450.340.221.16-0.350.010.060.06

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Net Cash Provided By Used In Investing Activities 23.1632.8017.7144.4221.1829.6833.43-53.5814.4320.5313.87-164.1639.5467.3836.9614.74-96.8825.2326.40-57.835.45-51.148.1312.08NANANANANANANANANANANANANANANANANA
Payments To Acquire Property Plant And Equipment NANANA0.000.000.000.04NANANANA0.17NANANA0.000.000.010.010.020.030.020.000.030.020.010.070.490.150.010.010.000.010.010.010.02NANA0.00NANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Net Cash Provided By Used In Financing Activities 1.120.000.560.020.100.180.0045.290.340.290.6938.470.400.200.070.03138.373.970.230.5493.9716.040.180.15NANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30
Revenues 4.876.936.173.2610.8123.004.790.8220.270.001.94112.099.275.638.094.515.795.214.385.535.062.870.000.000.000.910.000.000.080.010.002.440.870.490.911.120.960.180.971.029.97
Csl Vifor, Commercial Supply Revenue, 1.25NANANA3.37NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 4.876.936.173.2610.8123.004.790.8220.270.001.94112.099.275.638.094.515.795.214.385.535.062.870.000.000.000.910.000.000.080.010.002.440.870.490.911.120.960.180.971.029.97
Csl Vifor, Collaborative Revenue,, Csl Vifor Profit Sharing 1.93NANANA7.44NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Csl Vifor, Royalty,, Csl Vifor Kapruvia 0.17NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Clinical Compound Revenue 0.070.000.10NANANANA0.120.240.000.040.030.010.540.070.000.000.000.140.000.03NA0.000.00NANANANANANANANANANANANANANANANANA
Collaborative Revenue 2.475.412.751.137.448.00NA0.000.000.000.71NANANANANANANANANANANA0.000.00NANANANANANANANANANANANANANANANANA
Commercial Supply Revenue 1.251.403.192.063.370.004.79NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees 0.91NANA0.000.0015.00NA0.0020.030.001.19112.069.265.108.024.515.795.214.245.535.032.870.000.00NANANANANANANANANANANANANANANANANA
Royalty 0.170.120.12NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Clinical Compound Revenue, Maruishi Pharmaceutical Company Limited NA0.000.10NANANANA0.000.000.000.040.000.010.450.070.000.000.000.140.000.030.000.000.00NANANANANANANANANANANANANANANANANA
Collaborative Revenue, Csl Vifor NANA2.75NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue, Vifor NANANANA7.44NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Commercial Supply Revenue, Csl Vifor NA1.403.19NANA0.004.79NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Commercial Supply Revenue, Vifor NANANANA3.37NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, Vifor Fresenius Medical Care Renal Pharma Limited NANANANANA15.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Royalty, Csl Vifor, Csl Vifor Kapruvia NA0.120.12NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, Vifor Fresenius Medical Care Renal Pharma Limited, Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No2 NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue,, Csl Vifor Profit Sharing 1.93NANANA7.44NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue, Csl Vifor, Csl Vifor Profit Sharing NA5.412.75NANA8.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Commercial Supply Revenue,, Csl Vifor Korsuva 1.25NANANA3.37NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Royalty,, Csl Vifor Kapruvia 0.17NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Royalty, Csl Vifor, Csl Vifor Kapruvia NA0.120.12NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Clinical Compound Revenue, License Agreement With Maruishi Pharmaceutical Company Limited 0.07NANANANANANANA0.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue, Csl Vifor Profit Sharing NA5.412.75NANA8.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue, License Agreement With Maruishi Pharmaceutical Company Limited 0.54NANANANANANA0.000.000.000.71NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaborative Revenue, Vifor Profit Sharing NANANANA7.448.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Commercial Supply Revenue, Vifor NANANANA3.37NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, License Agreement With Maruishi Pharmaceutical Company Limited 0.91NANANANANANA0.000.000.001.19NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, Vifor NANANANA0.0015.00NANA20.03NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, Vifor Agreement No2 NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Royalty, Csl Vifor Kapruvia NANA0.12NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License And Milestone Fees, License Agreement With Vifor Fresenius Medical Care Renal Pharma Limited, Subsequent Event NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License Agreement With Maruishi Pharmaceutical Company Limited 1.45NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Other Nonoperating Income Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Inventory Net
NonCurrent Assets
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Operating Lease Liability
Current Liabilities
Operating Lease Liability Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Diluted Shares Outstanding
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Next Twelve Months
InventoryNet
Inventory Finished Goods

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('cara:LicenseAndMilestoneFees', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('cara:CollaborativeRevenue', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:CostOfGoodsAndServicesSold
us-gaap:ProductOrService, us-gaap:RelatedPartyTransaction
('cara:CommercialSupplyRevenueWithAssociatedCostsOfGoodsSold', None)
Cost Of Goods And Services Soldus-gaap: Product Or Service, us-gaap: Related Party Transaction
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InvestmentType
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueMeasurementsRecurring')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Measurement Frequency
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InvestmentType
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Investment Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('cara:LicenseAndMilestoneFees', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('cara:CollaborativeRevenue', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type